NURIX THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.74 USD | +3.65% |
|
-0.77% | +62.11% |
| 06-11 | Nurix Therapeutics Files Mixed Shelf Registration | MT |
| 06-11 | Certain Restricted Stock Units of Nurix Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-JUN-2024. | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 71.29M 5.55B | Sales 2025 * | 66.83M 5.2B | Capitalization | 958M 74.59B |
|---|---|---|---|---|---|
| Net income 2024 * | -171M -13.31B | Net income 2025 * | -224M -17.44B | EV / Sales 2024 * | 9.28 x |
| Net cash position 2024 * | 297M 23.1B | Net cash position 2025 * | 297M 23.11B | EV / Sales 2025 * | 9.89 x |
| P/E ratio 2024 * |
-5.48
x | P/E ratio 2025 * |
-4.86
x | Employees | 284 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.82% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +3.68% | ||
| 1 week | -0.77% | ||
| Current month | +6.22% | ||
| 1 month | +20.01% | ||
| 3 months | +16.34% | ||
| 6 months | +101.81% | ||
| Current year | +62.11% |
1 week
14.69
17.07
1 month
13.5517.28
Current year
7.6518.12
1 year
4.2218.12
3 years
4.2237.43
5 years
4.2252.38
10 years
4.2252.38
| Managers | Title | Age | Since |
|---|---|---|---|
Arthur Sands
CEO | Chief Executive Officer | 62 | 17/09/14 |
Hans van Houte
DFI | Director of Finance/CFO | 58 | 31/12/14 |
| Chief Tech/Sci/R&D Officer | - | 31/08/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Judith Reinsdorf
BRD | Director/Board Member | 60 | 30/09/21 |
Paul Silva
BRD | Director/Board Member | 58 | 30/09/21 |
Arthur Sands
CEO | Chief Executive Officer | 62 | 17/09/14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.70% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/06/24 | 16.74 | +3.65% | 177 508 |
| 11/06/24 | 16.15 | +5.42% | 633,738 |
| 10/06/24 | 15.32 | -2.30% | 695,307 |
| 07/06/24 | 15.68 | -3.98% | 322,090 |
| 06/06/24 | 16.33 | -3.14% | 426,869 |
Delayed Quote Nasdaq, June 12, 2024 at 03:46 pm
More quotes
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.15
USD
Average target price
24.67
USD
Spread / Average Target
+52.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +62.11% | 958M | |
| +17.75% | 124B | |
| +15.54% | 109B | |
| -7.03% | 23.84B | |
| +2.01% | 22.42B | |
| -14.18% | 17.5B | |
| -10.24% | 16.61B | |
| -41.64% | 16.43B | |
| +2.20% | 13.4B | |
| +26.46% | 11.47B |
- Stock Market
- Equities
- NRIX Stock